Chopra, Arvind <br/><br/>
Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study.  [electronic resource] 

 -  Clinical rheumatology  Apr 2016 
 - 1059-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1434-9949 
<br/><br/><label>Standard No.: </label>10.1007/s10067-015-2988-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antirheumatic Agents--administration & dosage<br/>Arthritis, Rheumatoid--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination--methods<br/>Female<br/>Humans<br/>India<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Patient Safety<br/>Reproducibility of Results<br/>Rheumatology--methods<br/>Surveys and Questionnaires<br/>Treatment Outcome